News for Carver Bancorp, Inc. (CARV)

PR NewswireNEW YORK, Jan. 27, 2025 -- Stockholders Re-Elect Jillian E. Joseph and Kenneth J. Knuckles to Serve on the Carver Board of Directors ---- Harlem

PR NewswireNEW YORK, Dec. 13, 2024 Preliminary results indicate approximately 70% of retail vote for new voices on Board of Directors, not including votes

PR NewswireNEW YORK, Dec. 9, 2024 Calls on shareholders to vote ahead of Annual Meeting ”“ Vote by 11:59 PM on December 11Says Carver's best days are ahea

Dream Chasers Urges Institutional Shareholders to Join Retail Holders to Drive Change at Carver

Leading Independent Proxy Advisory Firm ISS Recommends Carver Bancorp, Inc. Stockholders Vote FOR the Company's Highly Qualified Director Nominees

On November 25, 2024, Kenneth Knuckles, a Director at Carver Federal Savings Bank, a subsidiary of Carver Bancorp Inc (CARV), purchased 8,982 shares of the comp

On November 25, 2024, Craig Mackay, a Director at Carver Bancorp Inc, purchased 59,880 shares of the company, as reported in the SEC Filing. Following this tran

On November 25, 2024, JACKSON PAZEL G JR, a Director at Carver Federal Savings Bank, a subsidiary of Carver Bancorp Inc (CARV), purchased 8,982 shares of the co

PR NewswireNEW YORK, Nov. 26, 2024 Corrects Record on Board's Misleading Statements in Proxy ContestUrges Institutional and Retail Shareholders to Vote for

PR NewswireNEW YORK, Nov. 20, 2024 Carver Reported $2.1 Million Loss in Second Quarter, up from $1.48 Million Loss in Same Quarter 2023$25m in Losses Over

Carver Bancorp (CARV) experienced a significant stock movement with a rapid rise of 7.98%. The stock is currently priced at $1.76 per share, with a trading volu

On Wednesday, 311 stocks hit new 52-week lows.

In this piece, we will take a look at the 15 worst performing bank stocks in 2023.

Read Investment Analysts’ Upgrades for June 7th (AAUKF, ABC, ARCH, BHP, BTLCY, BTU, CARV, CBT, CGGYY, DD) at ETF Daily News

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) shares gained 100.4% to close at $4.75 on Monday after the FDA granted clearance for the company's pūrgo technology, classifying it as a class II medical device.